KCP-330-020 | Clinical Research Studies Listing

Recruiting

18 years - 99 years

All

Phase 2

6 participants needed

1 Location

Brief description of study

The purpose of this study is to see if the investigational drug, selinexor, has any effects in eligible participants with advanced unresectable dedifferentiated liposarcoma (DDLS). Selinexor will be given at a fixed oral dose of 60mg or placebo twice weekly on Days 1 and 3 during Weeks 1-6 of each 42 day cycle until disease progression, intolerability, consent withdrawal or unblinding in Phase 2, 3, and open-label portion of the study.

Detailed description of study

A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLEBLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Liposarcoma
Age: 18 years - 99 years
Gender: All

Updated on 19 Feb 2024. Study ID: 825937

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).